Clinical Trials Browser

Phase 2 × Unknown × Hemangiosarcoma × Clear all

Hemangiosarcoma

NCT00410462 2014-08-08

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

Malignant mesenchymal tumor, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT00003718 2014-01-06

Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma

Phase 2 Unknown

25 enrolled

GynecologicSarcoma

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Endometrial Neoplasms, Sarcoma, Endometrial Stromal, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT00874874 2009-12-24

Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery

Phase 2 Unknown

96 enrolled

Sarcoma

Hemangiosarcoma, Sarcoma

Clinical Trials

ASAP

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma

Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery